JeffreyL.JorgensenMDPhD

PubMed

• Multicolor flow cytometric immunophenotyping is highly sensitive and specific in identifying aberrant mast cells in the diagnostic workup of systemic mastocytosis.
  Medeiros, L., Nwogbo, O., Fang, H., Wang, W., Xu, J., Miranda, R., Bose, P., Ok, C., Jorgensen, J., Wang, S.> ;American Journal of Clinical Pathology. 2024 Feb 19
• 2 citations
  Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission.
  Fadi G Haddad, Nicholas J Short, Jayastu Senapati, Nitin Jain, Koji Sasaki, Yesid Alvarado, Xuemei Wang, Lucia Masarova, Farhad Ravandi, Elias Jabbour, Jeffrey Jorgens...> ;Blood. 2024 Feb 1
• 1 citations
  Durvalumab-induced Pure White Cell Aplasia.
  Ji Lin, Paola Rodriguez-Martinez, Thein Hlaing Oo, Shuyu E, Jeffrey Jorgensen, Cristhiam M Rojas-Hernandez> ;Journal of Immunotherapy. 2023 Oct 30
• 3 citations
  Validation of a 12-color flow cytometry assay for acute myeloid leukemia minimal/measurable residual disease detection.
  Sa A Wang, Jeffrey L Jorgensen, Shimin Hu, Fuli Jia, Shaoying Li, Sanam Loghavi, Chi Young Ok, Beenu Thakral, Jie Xu, L Jeffrey Medeiros, Wei Wang> ;Cytometry. Part B, Clinical Cytometry. 2023 Sep 1
• 8 citations
  Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity.
  Alexandre Bazinet, Tapan Kadia, Nicholas J Short, Gautam Borthakur, Sa A Wang, Wei Wang, Sanam Loghavi, Jeffrey Jorgensen, Keyur Patel, Courtney DiNardo, Naval Daver, ...> ;Blood Advances. 2023 Jul 11
• 2 citations
  Venetoclax consolidation in high-risk CLL treated with ibrutinib for ≥1 year achieves a high rate of undetectable MRD.
  Philip A Thompson, Michael J Keating, Alessandra Ferrajoli, Nitin Jain, Christine B Peterson, Naveen Garg, Sa A Wang, Jeffrey L Jorgensen, Tapan M Kadia, Prithviraj Bo...> ;Leukemia. 2023 Jul 1
• 11 citations
  Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia.
  Hagop Kantarjian, Fadi G Haddad, Nitin Jain, Koji Sasaki, Nicholas J Short, Sanam Loghavi, Rashmi Kanagal-Shamanna, Jeffrey Jorgensen, Issa Khouri, Partow Kebriaei, Ye...> ;Journal of Hematology & Oncology. 2023 May 2
• 15 citations
  Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results.
  Hagop Kantarjian, Nicholas J Short, Nitin Jain, Koji Sasaki, Xuelin Huang, Fadi G Haddad, Issa Khouri, Courtney D DiNardo, Naveen Pemmaraju, William Wierda, Guillermo ...> ;American Journal of Hematology. 2023 Mar 1
• 3 citations
  Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia.
  Farhad Ravandi, Robert J Kreitman, Enrico Tiacci, Leslie Andritsos, Versha Banerji, Jacqueline C Barrientos, Seema A Bhat, James S Blachly, Alessandro Broccoli, Timoth...> ;Blood Cancer Journal. 2022 Dec 13
• 5 citations
  Unique pathologic features and gene expression signatures distinguish blastoid high-grade B-cell lymphoma from B-acute lymphoblastic leukemia/lymphoma.
  Jie Xu, Pei Lin, Evan N Cohen, Guilin Tang, Sa A Wang, Mahsa Khanlari, Wei Wang, Joseph D Khoury, Sergej Konoplev, C Cameron Yin, Jeffrey L Jorgensen, Francisco Vega, ...> ;Haematologica. 2023 Mar 1
• 4 citations
  Flow cytometry immunophenotypic features of pure erythroid leukemia and the distinction from reactive erythroid precursors.
  Hong Fang, Sa A Wang, M James You, Shimin Hu, Roberto N Miranda, Zhenya Tang, Pei Lin, Jeffrey L Jorgensen, Jie Xu, Beenu Thakral, Ellen J Schlette, Siba El Hussein, C...> ;Cytometry. Part B, Clinical Cytometry. 2022 Nov 1
• 8 citations
  Blinatumomab is associated with favorable outcomes in patients with B-cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold...
  Elias J Jabbour, Nicholas J Short, Nitin Jain, Nadya Jammal, Jeffrey Jorgensen, Sa Wang, Xuemei Wang, Maro Ohanian, Yesid Alvarado, Tapan Kadia, Koji Sasaki, Rebecca G...> ;American Journal of Hematology. 2022 Sep 1
• 7 citations
  Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease (MRD) recurrence following ...
  Nicholas J Short, Walid Macaron, Tapan Kadia, Courtney Dinardo, Ghayas C Issa, Naval Daver, Sa Wang, Jeff Jorgensen, Daniel Nguyen, Aram Bidikian, Keyur P Patel, Sanam...> ;American Journal of Hematology. 2022 Nov 1
• 31 citations
  High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse.
  Nicholas J Short, Hagop Kantarjian, Farhad Ravandi, Marina Konopleva, Nitin Jain, Rashmi Kanagal-Shamanna, Keyur P Patel, Walid Macaron, Tapan M Kadia, Sa Wang, Jeffre...> ;Blood Advances. 2022 Jul 12
• 8 citations
  Acute promyelocytic leukemia: Immunophenotype and differential diagnosis by flow cytometry.
  Hong Fang, Sa A Wang, Shimin Hu, Sergej N Konoplev, Huan Mo, Wei Liu, Zhuang Zuo, Jie Xu, Jeffrey L Jorgensen, C Cameron Yin, Siba El Hussein, Fatima Zahra Jelloul, Zh...> ;Cytometry. Part B, Clinical Cytometry. 2022 Jul 1
• 6 citations
  Comprehensive immunophenotypic study of acute myeloid leukemia with KMT2A (MLL) rearrangement in adults: A single-institution experience.
  Sergej Konoplev, Xiaoqiong Wang, Guilin Tang, Shaoying Li, Wei Wang, Jie Xu, Sherry A Pierce, Fuli Jia, Jeffrey L Jorgensen, Farhad Ravandi, Ghayas C Issa, L Jeffrey M...> ;Cytometry. Part B, Clinical Cytometry. 2022 Mar 1
• 16 citations
  Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial.
  Michael L Wang, Preetesh Jain, Shuangtao Zhao, Hun Ju Lee, Loretta Nastoupil, Luis Fayad, Chi Young Ok, Rashmi Kanagal-Shamanna, Holly A Hill, Yixin Yao, Fredrick B Ha...> ;The Lancet. Oncology. 2022 Mar 1
• 27 citations
  Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party.
  Jesse M Tettero, Sylvie Freeman, Veit Buecklein, Adriano Venditti, Luca Maurillo, Wolfgang Kern, Roland B Walter, Brent L Wood, Christophe Roumier, Jan Philippé, Barba...> ;Hemasphere. 2022 Jan 1
• 205 citations
  2021 Update Measurable Residual Disease in Acute Myeloid Leukemia: European LeukemiaNet Working Party Consensus Document.
  Michael Heuser, Sylvie D. Freeman, Gert J. Ossenkoppele, Francesco Buccisano, Christopher S. Hourigan, Lok Lam Ngai, Jesse Marc Tettero, Costa Bachas, Constance Baer, ...> ;Blood. 2021 Nov 1
• 12 citations
  Bone Marrow versus Peripheral Blood Grafts for Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide.
  Rohtesh S. Mehta, Rima M. Saliba, Leonard C. Alsfeld, Jeffrey L. Jorgensen, Sa A. Wang, Paolo Anderlini, Gheath Alatrash, Qaiser Bashir, Stefan O. Ciurea, Chitra Hosin...> ;Transplantation and Cellular Therapy. 2021 Sep 16
• 2 citations
  Hematogones with light chain restriction: A potential diagnostic pitfall when using flow cytometry analysis to assess bone marrow specimens
  Siba El Hussein, Wei Wang, Sa A. Wang, Hong Fang, Sofia Garces, Mehrnoosh Tashakori, Kirill A. Lyapichev, Xiaoqiong Wang, Sanam Loghavi, L. Jeffrey Medeiros, Pramoda C...> ;Leukemia Research. 2021 Sep 8
• 3 citations
  Blastic plasmacytoid dendritic cell neoplasm with history of myeloma and concomitant acute undifferentiated leukemia: Illustration of morphologic and immunophenotypic ...
  Siba El Hussein, Wei Wang, Sa A. Wang, Sanam Loghavi, Xiaoqiong Wang, Hong Fang, L. Jeffrey Medeiros, Phyu P. Aung, Carlos Antonio Torres Cabala, Jeffrey L. Jorgensen,...> ;Leukemia & Lymphoma. 2021 Jul 24
• 9 citations
  Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propen...
  Koji Sasaki, Hagop M. Kantarjian, Kiyomi Morita, Nicholas J. Short, Marina Konopleva, Nitin Jain, Farhad Ravandi, Guillermo Garcia-Manero, Sa Wang, Joseph D. Khoury, J...> ;Cancer. 2021 Sep 15
• 42 citations
  Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial.
  Nitin Jain, Michael J. Keating, Philip A. Thompson, Alessandra Ferrajoli, Jan A. Burger, Gautam Borthakur, Koichi Takahashi, Zeev Estrov, Koji Sasaki, Nathan Fowler, T...> ;JAMA Oncology. 2021 Aug 1
• 19 citations
  Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations
  Nitin Jain, Philip A. Thompson, Jan A. Burger, Alessandra Ferrajoli, Koichi Takahashi, Zeev Estrov, Gautam Borthakur, Prithviraj Bose, Tapan M. Kadia, Naveen Pemmaraju...> ;Leukemia. 2021 May 18
• Join now to see all

Journal Articles

• CD123 Expression Patterns and Selective Targeting with a CD123-Specific Antibody-Drug Conjugate (IMGN632) in Acute Lymphoblastic Leukemia  
  L Jeffrey Medeiros, Hagop M Kantarjian, Jeffrey L Jorgensen, Marina Konopleva, Elias J Jabbour, Joseph D Khoury, Sa A Wang, Sergej N Konoplev, Haematologica

Abstracts/Posters

• Phase II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL) with Positive Measurable Residual Disease (MRD)
  Jeffrey L. Jorgensen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)
  Jeffrey L. Jorgensen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)
  Jeffrey L. Jorgensen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Allogeneic Hematopoietic Cell Transplantation May Improve Long-Term Outcomes in Patients with Ph-like Acute Lymphoblastic Leukemia with CRLF2 Overexpression
  Jeffrey L. Jorgensen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• The Early Achievement of Measurable Residual Disease Negativity in the Treatment of Adults with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia Is a Strong P...
  Jeffrey L. Jorgensen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of IGHV-Mutated CLL and without Del(17p)/Mutated TP53
  Jeffrey L. Jorgensen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Achievement of Complete Remission (CR) with Measurable Residual Disease (MRD) Negativity Is Highly Prognostic in Patients (pts) with Relapsed or Refractory (R/R) Acute...
  Jeffrey L. Jorgensen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Long-Term Safety and Efficacy of Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
  Jeffrey L. Jorgensen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in O...
  Jeffrey L. Jorgensen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Identification of Gene Expression Signatures in Leukemia Stem Cells and Minimal Residual Disease Following Treatment of Adverse Risk Acute Myeloid Leukemia
  Jeffrey L. Jorgensen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Outcome of Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) without 3-Month Complete Molecular Response (CMR)
  Jeffrey L. Jorgensen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromoso... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Combined Ibrutinib and Venetoclax in Patients with Treatment-Naïve High-Risk Chronic Lymphocytic Leukemia (CLL) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018